GRDN Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.8%, SMA50 5.39%, SMA200 25.34%). The stock’s 14-day RSI is 54.6 (neutral), while the ATR of 1.3 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.65% below its high and over 86.0% above its low. Average 10-day trading volume of 478.61 thousand shares is slightly above the 3-month average of 416.30 thousand, indicating heightened recent market interest.

Guardian Pharmacy Services, Inc. has 22.73 million shares outstanding. The public float is 19.45 million shares, elevated short interest at 4.09% of float. This equals 515.10 thousand shares. The short ratio is 3.03 days. Institutional investors hold 97.75% of the float. Insiders own 15.09%. Salentine Thomas J Jr holds 4.47 million shares, BINDLEY WILLIAM E has 4.47 million shares and Bindley Capital Partners I, LLC has 4.47 million shares. Over the past six months, insider transactions show net selling. They sold 13.30 million shares across 9 transactions.

Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $44.00 to $30.00. The high target offers 21.92% upside. The low target suggests -16.87% downside. The mean target is $37.80. This offers 4.74% upside. Guardian Pharmacy Services, Inc. earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by -12.5%. The prior quarter beat by 37.04%. Over the last six quarters, Apple has recorded several small beats. These include 14.29% in March 26, 2025.

Guardian Pharmacy Services, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $71.57. This means the shares are trading below this model’s fair value.

Guardian Pharmacy Services, Inc. (NYSE:GRDN) closed at $36.09 USD, losing -$0.18 (-0.50%) from the previous close of $36.27. The stock is currently mid-range between its 52-week high and low $19.17 and $41.36. With a market capitalization of about $2.29 billion, Guardian Pharmacy Services, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.09). Key stats such as the average daily volume over the past year has been around 435.24 thousand shares, in line with its 52-week average. Headquartered in Atlanta, GA, Guardian Pharmacy Services, Inc. operates in the Healthcare sector and the Medical - Distribution industry. Led by CEO Fred Burke, the company employs approximately 3,400 people and listed since April 21, 2016. Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States.

Guardian Pharmacy Services, Inc. trades at a P/E ratio of 43.41, slightly above the S&P 500 average, with a price-to-sales ratio of 1.58 and a price-to-book ratio of 9.91 trading at moderately above to book value. The P/FCF stands at 32.9, also below market averages.

Our AI price prediction model suggests that Guardian Pharmacy Services, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.91%, with price expected at $34.68 by May 22, 2026, within a range of $33.52 to $35.88 3-Month Outlook: Projected fall of -38.9%, reaching $22.05 by August 06, 2026, with a range of $20.72 to $23.15. 1-Year Outlook: Projected gain of 39.24%, with price at $50.25 by May 07, 2027, within a range of $49.29 to $51.05.

Guardian Pharmacy Services, Inc. (NYSE:GRDN) shares are flat -5.88% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Guardian Pharmacy Services, Inc. trading at a premium to the broader market with a P/E of 43.41. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $36.55, suggesting 1.27% upside. Our AI forecast model points to short-term weakness (-3.91% over two weeks), a medium-term fall (-38.9% over three months), and a longer-term gain (39.24% over one year), with expected trading ranges indicating moderate volatility.